Evaluating the effects of Danhong injection in treatment of acute ischemic stroke: study protocol for a multicenter randomized controlled trial

Bing Li, Yilong Wang, Jingjing Lu, Jun Liu, Ye Yuan, Yanan Yu, Pengqian Wang, Xingquan Zhao, Zhong Wang, Bing Li, Yilong Wang, Jingjing Lu, Jun Liu, Ye Yuan, Yanan Yu, Pengqian Wang, Xingquan Zhao, Zhong Wang

Abstract

Background: Danhong injection (DHI) has been widely prescribed to patients with acute ischemic stroke (AIS). However, due to methodological deficiencies, previous research has not yet provided rigorous evidence to support the use of DHI in the treatment of AIS. Therefore, we designed this multicenter, randomized, controlled, and double-blind trial to evaluate the efficacy and safety of DHI for AIS.

Methods/design: It is a randomized, multicenter, double-blind, placebo-controlled, adaptive clinical trial. A total of 864 eligible patients will be randomized into either the DHI or placebo group in a 2:1 ratio. All patients will be given the standard medical care as recommended by guidelines. Participants will undergo a 2-week treatment regimen and 76-day follow-up period. The primary outcome is the proportion of patients with a favorable outcome, defined as a score of 0-1 on the modified Rankin scale at day 90. Secondary outcomes include a change in the total score of the Chinese medicine symptom scales of "Xueyu Zheng" (blood stasis syndrome), the proportion of patients with a Barthel Index score of ≥90, the proportion of patients with an improvement in NIHSS score of ≥4 or NIHSS score of 0-1, quality of life measured by the EQ-5D scale, etc. Safety outcomes such as global disability (mRS ≥3) at day 90 will also be assessed. The changes in mRNA and microRNA profiles in 96 patients selected from certain centers will also be assessed. As this is an adaptive design, two interim analyses are prospectively planned, which will be carried out after one-third and two-thirds of patients have completed the trial, respectively. Based on the results of the interim analyses, the Data Monitoring Committee (DMC) will decide how to modify the study.

Discussion: This trial will provide high-quality evidence for DHI in treatment of AIS.

Trial registration: Clinical Trials.gov NCT01677208 (Date of registration 22 December 2012).

Figures

Fig. 1
Fig. 1
The flow diagram of this trial

References

    1. Matsuo R, Kamouchi M, Ago T, Hata J, Shono Y, Kuroda J, et al. Thrombolytic therapy with intravenous recombinant tissue plasminogen activator in Japanese older patients with acute ischemic stroke: the Fukuoka Stroke Registry. Geriatr Gerontol Int. 2014;14:954–9. doi: 10.1111/ggi.12205.
    1. Chen J, Venkat P, Zacharek A, Chopp M. Neurorestorative therapy for stroke. Front Hum Neurosci. 2014;8:382.
    1. Turner RC, Lucke-Wold B, Lucke-Wold N, Elliott AS, Logsdon AF, Rosen CL, et al. Neuroprotection for ischemic stroke: moving past shortcomings and identifying promising directions. Int J Mol Sci. 2013;14:1890–917. doi: 10.3390/ijms14011890.
    1. Behravan E, Razavi BM, Hosseinzadeh H. Review of plants and their constituents in the therapy of cerebral ischemia. Phytother Res. 2014;28:1265–74. doi: 10.1002/ptr.5187.
    1. Li X, Tang J, Meng F, Li C, Xie Y. Study on 10 409 cases of post-marketing safety Danhong injection centralized monitoring of hospital. Zhongguo Zhong Yao Za Zhi. 2011;36:2783–5.
    1. Wang Z, Song F, Li J, Zhang Y, He Y, Yang J, et al. PET demonstrates functional recovery after treatment by Danhong injection in a rat model of cerebral ischemic-reperfusion injury. eCAM. 2014;2014:430757.
    1. Wang S, Guo H, Wang X, Chai L, Hu L, Zhao T, et al. Pretreatment with Danhong injection protects the brain against ischemia-reperfusion injury. Neural Regen Res. 2014;9:1453–9. doi: 10.4103/1673-5374.139462.
    1. He Y, Wan H, Du Y, Bie X, Zhao T, Fu W, et al. Protective effect of Danhong injection on cerebral ischemia-reperfusion injury in rats. J Ethnopharmacol. 2012;144:387–94. doi: 10.1016/j.jep.2012.09.025.
    1. Ma L, Wang S, Li K. A systematic review of Danhong injection treatment for acute cerebral ischemic stroke and the safety of this treatment. Journal of Emergency in Traditional Chinese Medicine. 2012;10:1609–10.
    1. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357:562–71. doi: 10.1056/NEJMoa070240.
    1. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–29. doi: 10.1056/NEJMoa0804656.
    1. Chinese Society of Neurology China Guideline for the Diagnosis and Treatment of Acute Ischemic Stroke. Chin J Neurol. 2010;43:146–53.
    1. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604–7. doi: 10.1161/01.STR.19.5.604.
    1. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61–5.
    1. Wityk RJ, Pessin MS, Kaplan RF, Caplan LR. Serial assessment of acute stroke using the NIH Stroke Scale. Stroke. 1994;25:362–5. doi: 10.1161/01.STR.25.2.362.
    1. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72. doi: 10.1016/0168-8510(96)00822-6.
    1. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736–47. doi: 10.1161/CIRCULATIONAHA.110.009449.
    1. Yu Y, Hu S, Li G, Xue J, Li Z, Liu X, et al. Comparative effectiveness of Di’ao Xin Xue Kang capsule and Compound Danshen tablet in patients with symptomatic chronic stable angina. Sci Rep. 2014;4:7058. doi: 10.1038/srep07058.
    1. Cirulli J, McMillian WD, Saba M, Stenehjem D. Adaptive trial design: its growing role in clinical research and implications for pharmacists. Am J Health Syst Pharm. 2011;68:807–13. doi: 10.2146/ajhp100298.
    1. Tang H, Gu BL, Zhou XM. Study on the scores of blood stasis syndrome of acute ischemic stroke and its correlation with TOAST subtypes. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012;32:1500–2.
    1. He ZQ, Ji RZ, Wang X, Liang C, Wu ZG. Effect of advanced glycation end products on the function and angiogenesis of adipose tissue-derived stem cells and the protective effect of danhong injection: an experimental study. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014;34:839–45.
    1. Deng W, Yang C, Xiong M, Fu X, Lai H, Huang W. Danhong enhances recovery from residual dizziness after successful repositioning treatment in patients with benign paroxysmal positional vertigo. Am J Otolaryngol. 2014;35:753–7. doi: 10.1016/j.amjoto.2014.07.001.
    1. Chen J, Deng J, Zhang Y, Yang J, He Y, Fu W, et al. Lipid-lowering effects of Danhong injection on hyperlipidemia rats. J Ethnopharmacol. 2014;154:437–42. doi: 10.1016/j.jep.2014.04.023.
    1. Sun K, Fu C, Nie S, You Y. The index and improvement effect of using Danhong injection to patients with atherosclerosis symptoms of coronary heart disease (CHD) Pak J Pharm Sci. 2014;27:1699–704.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する